330 related articles for article (PubMed ID: 22115131)
1. Platinum anticancer drugs. From serendipity to rational design.
Monneret C
Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
[TBL] [Abstract][Full Text] [Related]
2. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
3. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
Kelland L
Expert Opin Investig Drugs; 2007 Jul; 16(7):1009-21. PubMed ID: 17594186
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin: a review of preclinical and clinical studies.
Raymond E; Chaney SG; Taamma A; Cvitkovic E
Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
[TBL] [Abstract][Full Text] [Related]
6. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
7. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
8. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
10. The state-of-play and future of platinum drugs.
Apps MG; Choi EH; Wheate NJ
Endocr Relat Cancer; 2015 Aug; 22(4):R219-33. PubMed ID: 26113607
[TBL] [Abstract][Full Text] [Related]
11. Platinum compounds: a hope for future cancer chemotherapy.
Ali I; Wani WA; Saleem K; Haque A
Anticancer Agents Med Chem; 2013 Feb; 13(2):296-306. PubMed ID: 22583420
[TBL] [Abstract][Full Text] [Related]
12. The status of platinum anticancer drugs in the clinic and in clinical trials.
Wheate NJ; Walker S; Craig GE; Oun R
Dalton Trans; 2010 Sep; 39(35):8113-27. PubMed ID: 20593091
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
14. [Platinum compounds: metabolism, toxicity and supportive strategies].
Lipp HP; Hartmann JT
Praxis (Bern 1994); 2005 Feb; 94(6):187-98. PubMed ID: 15754530
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
16. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
17. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
Sooriyaarachchi M; Narendran A; Gailer J
Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
19. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
20. New strategies against prostate cancer--Pt(II)-based chemotherapy.
Matos CS; de Carvalho AL; Lopes RP; Marques MP
Curr Med Chem; 2012; 19(27):4678-87. PubMed ID: 22856665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
